Articles in the Watchlist Category
Analysis, Watchlist »
Universal Biosensors (ASX:UBI) is hoping to crack the tough $10B glucose testing market via a partnership with J&J’s LifeScan. UBI’s main product the One Touch Verio is the most accurate glucose self testing meter currently available. The One Touch Verio is currently only available in the Netherlands (launched Jan 2010) and Australia (Sept 2010), though J&J are planning on launching in the US in 2011.
UBI is yet to obtain profitability and is dependent on J&J sales and marketing in a very crowded and competitive landscape. While the One Touch Verio is currently the most …
Analysis, Watchlist »
In the next seven months Telstra will cough up 28cents dividend, that’s 40cents pre-tax. Over such a short time frame a valuation makes little sense as the voting machine will determine the price. However what this chart shows is that at the current price of $2.80 Telstra presents an excellent short term opportunity with an attractive risk/return profile.








